Literature DB >> 9431977

Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons.

D Brambilla1, S Leung, J Lew, J Todd, S Herman, M Cronin, D E Shapiro, J Bremer, C Hanson, G V Hillyer, G D McSherry, R S Sperling, R W Coombs, P S Reichelderfer.   

Abstract

Use of a common set of human immunodeficiency virus type 1 (HIV-1) RNA standards eliminated differences among absolute HIV-1 RNA copy number estimates made with three commercially available assays. The relative changes in the viral RNA levels determined by the commercial assays were similar and were unaffected by the use of a common set of standards.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9431977      PMCID： PMC124864     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  19 in total

Review 1.  Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.

Authors:  C C Carpenter; M A Fischl; S M Hammer; M S Hirsch; D M Jacobsen; D A Katzenstein; J S Montaner; D D Richman; M S Sáag; R T Schooley; M A Thompson; S Vella; P G Yeni; P A Volberding
Journal:  JAMA       Date:  1996-07-10       Impact factor: 56.272

Review 2.  HIV viral load markers in clinical practice.

Authors:  M S Saag; M Holodniy; D R Kuritzkes; W A O'Brien; R Coombs; M E Poscher; D M Jacobsen; G M Shaw; D D Richman; P A Volberding
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

3.  Quantification of HIV-1 RNA in plasma: comparable results with the NASBA HIV-1 RNA QT and the AMPLICOR HIV monitor test.

Authors:  A M Vandamme; J C Schmit; S Van Dooren; K Van Laethem; E Gobbers; W Kok; P Goubau; M Witvrouw; W Peetermans; E De Clercq; J Desmyter
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-10-01

4.  Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICOR-HIV monitor, and QUANTIPLEX HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  H Revets; D Marissens; S de Wit; P Lacor; N Clumeck; S Lauwers; G Zissis
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

5.  Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  R S Sperling; D E Shapiro; R W Coombs; J A Todd; S A Herman; G D McSherry; M J O'Sullivan; R B Van Dyke; E Jimenez; C Rouzioux; P M Flynn; J L Sullivan
Journal:  N Engl J Med       Date:  1996-11-28       Impact factor: 91.245

6.  Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories.

Authors:  B Yen-Lieberman; D Brambilla; B Jackson; J Bremer; R Coombs; M Cronin; S Herman; D Katzenstein; S Leung; H J Lin; P Palumbo; S Rasheed; J Todd; M Vahey; P Reichelderfer
Journal:  J Clin Microbiol       Date:  1996-11       Impact factor: 5.948

7.  HIV quantification: clinical applications.

Authors:  P A Volberding
Journal:  Lancet       Date:  1996-01-13       Impact factor: 79.321

8.  An enhanced-sensitivity branched-DNA assay for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  D Kern; M Collins; T Fultz; J Detmer; S Hamren; J J Peterkin; P Sheridan; M Urdea; R White; T Yeghiazarian; J Todd
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

9.  Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  R Schuurman; D Descamps; G J Weverling; S Kaye; J Tijnagel; I Williams; R van Leeuwen; R Tedder; C A Boucher; F Brun-Vezinet; C Loveday
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

10.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245
View more
  15 in total

Review 1.  Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. TUBE Meeting Workshop Attendees. Technology Utilization for HIV-1 Blood Evaluation and Standardization in Pediatrics.

Authors:  J Lew; P Reichelderfer; M Fowler; J Bremer; R Carrol; S Cassol; D Chernoff; R Coombs; M Cronin; R Dickover; S Fiscus; S Herman; B Jackson; J Kornegay; A Kovacs; K McIntosh; W Meyer; N Michael; L Mofenson; J Moye; T Quinn; M Robb; M Vahey; B Weiser; T Yeghiazarian
Journal:  J Clin Microbiol       Date:  1998-06       Impact factor: 5.948

2.  Comparison of NucliSens and Roche Monitor assays for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma.

Authors:  J R Dyer; C D Pilcher; R Shepard; J Schock; J J Eron; S A Fiscus
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

3.  Comparison of two amplification technologies for detection and quantitation of human immunodeficiency virus type 1 RNA in the female genital tract. Division of AIDS Treatment Research Initiative 009 Study Team.

Authors:  J Bremer; M Nowicki; S Beckner; D Brambilla; M Cronin; S Herman; A Kovacs; P Reichelderfer
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

4.  Longitudinal variability of human immunodeficiency virus type 1 RNA viral load measurements by nucleic acid sequence-based amplification and NucliSens assays in a large multicenter study.

Authors:  M J Nowicki; L Benning; J W Bremer; W A Meyer; C Hanson; D Brambilla; S Silver; A Kovacs
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

5.  Effects of anticoagulant, processing delay, and assay method (branched DNA versus reverse transcriptase PCR) on measurement of human immunodeficiency virus type 1 RNA levels in plasma.

Authors:  L M Kirstein; J W Mellors; C R Rinaldo; J B Margolick; J V Giorgi; J P Phair; E Dietz; P Gupta; C H Sherlock; R Hogg; J S Montaner; A Muñoz
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

6.  Evaluation of the abbott LCx HIV-1 RNA quantitative, a new assay for quantitative determination of human immunodeficiency virus type 1 RNA.

Authors:  N Zanchetta; G Nardi; L Tocalli; L Drago; C Bossi; F R Pulvirenti; C Galli; M R Gismondo
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

7.  HIV dynamics in seminal plasma during primary HIV infection.

Authors:  Joanne Stekler; Brian J Sycks; Sarah Holte; Janine Maenza; Claire E Stevens; Joan Dragavon; Ann C Collier; Robert W Coombs
Journal:  AIDS Res Hum Retroviruses       Date:  2008-10       Impact factor: 2.205

8.  Stability of human immunodeficiency virus type 1 RNA in cerebrospinal fluid determined with the AMPLICOR HIV-1 MONITOR test, version 1.5 (ultrasensitive).

Authors:  Elyse J Singer; H Aaron Aronow; Shing-Yi Lee; Charles H Hinkin; Tadd Lazarus
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

9.  Comparison of versions 1.0 AND 1.5 of the UltraSensitive AMPLICOR HIV-1 MONITOR test for subjects with low viral load.

Authors:  J Brooks Jackson; Estelle Piwowar-Manning; LeTanya Johnson-Lewis; Roland Bassett; Lisa M Demeter; Donald Brambilla
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

10.  Comparison of the QUANTIPLEX HIV-1 RNA 2.0 assay with the AMPLICOR HIV-1 MONITOR 1.0 assay for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma of patients receiving stavudine-didanosine combination therapy.

Authors:  M Segondy; J Izopet; I Pellegrin; B Montes; B Dumon; C Pasquier; M Peeters; H J Fleury; J Puel; J Reynes
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.